this would seem to bode well for tyzeka. even if their head to head shows comparable efficacy and fails superiority (which frankly is the likely outcome imo), based on more favorable pricing, lack of food interaction, preg cat B safety designation, they should at least meet or perhaps exceed baraclude down the road in market share
I think this also supports the notion that:
1. more hep b patients are seeking treatment as the risk-benefit with more efficacious and tolerable therapies shifts towards treatment versus expectant management (this was already discussed on this board and a nice idix slide confimrs this)
2. some shift in market share away from adefovir and lamivudine (and perhaps peg) due to clear efficacy advantage of the newer antivirals (baraclude and tyzeka)
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM